Absci(US:ABSI)2023-03-24 16:58Absci's Integrated Drug Creation Platform - Absci is developing an Integrated Drug Creation platform that combines proprietary wet-lab assays capable of generating billions of protein-protein interactions a week for machine learning (ML) training with a scalable wet-lab infrastructure capable of validating 2.8 million unique AI-generated designs a week[17] - Absci's platform aims to accelerate drug discovery by enabling de novo drug creation with 'zero-shot' generative AI, demonstrated across four therapeutic targets[31] - Absci's rapid cycle times allow for rapid iteration and improvement of AI models, reduction of preclinical development timelines, and increased probability of success[22, 24] AI-Driven Antibody Design and Optimization - Absci is the first to design and validate new antibodies with zero-shot generative AI[26] - Absci's AI model generated highly diverse and effective binders from a massive search space[35] - 85% of the top 100 "natural" Trastuzumab variants exhibit higher-affinity than wild-type[50] Novel Target Discovery and Bionic Protein Technology - Absci's workflow identifies antigens targeted by exceptional immune responses, with >6,600 reconstructed antibodies and >250 hits under evaluation[63] - Absci is advancing a high-yielding SoluPro platform that enables selective site-specific non-standard amino acid (nsAA) incorporation into difficult-to-produce biologics[68] Partnerships and Financial Position - Merck has invested $610 million in biobucks for Absci drug discovery pact[103] - Absci has >$180M of cash, cash equivalents and short-term investments[98]